The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1425
Ado-Trastuzumab Emtansine (Kadcyla) for HER2-Positive Metastatic Breast Cancer
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Ado-trastuzumab emtansine (Kadcyla – Genentech), a human epidermal growth factor receptor 2 (HER2)-targeted antibody and microtubule inhibitor conjugate, has been approved by the FDA for intravenous (IV) treatment of HER2-positive metastatic breast cancer in patients previously treated with trastuzumab (Herceptin) and a taxane. The prefix was added to the new conjugate’s name at the request of the FDA to distinguish it from trastuzumab.

MECHANISM OF ACTION — HER2, a transmembrane receptor protein involved in normal cell growth, is overexpressed in about 15-20% of breast cancers.1,2 Amplification of HER2 is associated with more aggressive disease and reduced survival.3 Adotrastuzumab emtansine binds to the HER2 receptor, is internalized, and undergoes lysosomal degradation to trastuzumab and the microtubule inhibitor ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Ado-Trastuzumab Emtansine (Kadcyla) for HER2-Positive Metastatic Breast Cancer
Article code: 1425b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian